AI Terminal

MODULE: AI_ANALYST

Interactive Q&A, Risk Assessment, Summarization

MODULE: DATA_EXTRACT

Excel Export, XBRL Parsing, Table Digitization

MODULE: PEER_COMP

Sector Benchmarking, Sentiment Analysis

SYSTEM ACCESS LOCKED

Authenticate / Register Log In

Medistim

Remuneration Information • May 28, 2025

3662_dirs_2025-05-28_84404b02-eb92-427e-9248-622fa9d39a0a.html

Remuneration Information

Open in Viewer

Opens in native device viewer

CEO share program

Medistim ASA has transferred 10 000 shares to CEO Kari Krogstad's 100% owned company K2 Consulting. This is according to the agreement entered between Medistim ASA and the CEO under the same terms as described in the annual report. The shares have a lock up period of 3 years and this qualifies for a 25% discount. Average share price in the 14 days subscription period was NOK 173 per share. The shares were therefore purchased at 129,78 per share. To finance the purchase, Medistim has given the CEO a loan and when the lock in period has ended, she is given a bonus equal to the loan amount. K2 Consulting AS has in total 33.500 shares after the purchase. After these transactions Kari E. Krogstad controls in total 80.583 Medistim shares. Medistim ASA has 83.117 own shares after the transactions.